Objective-To investigate if the increased concentrations of stromelysin (MMP-3) found in the synovial fluid (SF) of patients with various arthritides reflect the concentrations in the circulation. Methods-Using a double antibody ELISA, we have measured proMMP-3 concentrations in sera from these patient groups and in others with a heightened acute phase response (APR) as a result of multiple organ failure. Results-The median serum concentration of proMMP-3 was increased by up to ninefold in the inflammatory arthritides, but not in osteoarthritis or in patients with a heightened APR resulting from a non-chronic inflammatory condition. Conclusion-In chronic inflammatory diseases such as rheumatoid arthritis, serum proMMP-3 may prove to be a more specific indicator of monokine activity than currently available serum markers.
Rheumatoid synovial fibroblasts exposed in vitro to the proinflammatory monokines interleukin-1 (IL-1) or tumour necrosis factor ax (TNFot) produce a number of matrix metalloproteinases (MMP), including MMP-1, -2, -3, and -9, of which the most abundant is MMP-3, previously called stromelysin.1-3 A similar predominance of MMP-3 over MMP-1 has recently been reported for synovial fluids (SF) from patients with rheumatoid arthritis (RA), in which the mean MMP-3 concentration was more than 40 ,ug/ml.4 Increased fluid concentrations of MMP-3 compared with control were also found in osteoarthritis (OA), but these were only approximately 10% of those in rheumatoid fluids,5 presumably reflecting the greater involvement of inflammatory monokines in RA. Increased joint concentrations of MMPs may contribute to the pathology of these diseases as, when tested in vitro, members of this enzyme family can degrade virtually all the articular cartilage components.6 Thus MMP-3 was shown to have the potential to degrade the proteoglycan component of cartilage,7 but recent analysis of aggrecan fragments from joint fluids of patients with various inflammatory arthritides suggested a major contribution from an as yet unidentified enzyme. 8 The MMPs are secreted from cells in a proenzyme form and within rheumatoid SF the majority of the MMP-3 was found to be present in this inactive form (pro-MMP-3). 4 In this study we examined whether this localised high concentration of proMMP-3 within SF was reflected in the circulation of patients with RA. Using a double antibody ELISA developed for proMMP-3, we compared the serum concentrations in patients with both inflammatory and non-inflammatory arthritides, with those of a normal control group. We also measured proMMP-3 in paired serum and SF samples collected before intraarticular injection of steroid which, if the inflamed joint were the major source of circulatory proMMP-3, would demonstrate a significant degree of association. Furthermore, in view of th_ir ability to inhibit both production and action of monokines, we examined the effect on serum proMMP-3 of corticosteroids directly administered to the inflamed joints of RA patients. Finally, we compared the serum concentrations of proMMP-3 and C reactive protein (CRP), because the latter is regarded as a reliable indicator of disease activity in RA. These two serum components were also measured in a group of critically ill patients with multiple organ failure who would be at the height of an acute phase response, with a markedly increased serum CRP concentration.
Patients and methods

PATIENTS AND SAMPLES
Blood samples were collected from 40 Lawrence score) were also selected for the study. Twenty samples for the control were obtained from "in house" members of staff. Table 1 gives details of these groups. In addition, sera from 20 patients with ankylosing spondylitis (AS) who had symptoms consistent with the New York criteria'0 and from 20 patients with reactive arthritis (ReA), based on clinical and laboratory findings, were assayed for proMMP-3. Paired serum and SF samples were collected before intra-articular injection of steroid in patients with various inflammatory arthritides and blood was also obtained from 13 RA patients before and 14 days after receiving such an injection of 80 mg of methyl prednisolone (Upjohn, Crawley, United Kingdom) into the knee. SF were centrifuged to remove cells and stored at -20°C until assayed by enzyme linked immunosorbent assay (ELISA). Serum samples from a group of patients (n = 20) with multiple organ failure, brought on in most cases by sepsis, road traffic accident or adult respiratory distress syndrome were also assayed as a patient group with an expected increased acute phase response.
DOUBLE ANTIBODY ELISA FOR proMMP -3 Rabbit and sheep polyclonal antisera to human proMMP-3, purified from IL-11WfTNFot-stimulated rheumatoid synovial fibroblast culture media,7 were raised with the help of Drs D E Woolley (University Hospital of South Manchester, United Kingdom) and R Drew (The Binding Site, Birmingham, United Kingdom), respectively. Neither antisera showed any cross reactivity to MMP-1, -2 or -9 when tested by Western blotting. The IgG fraction of the rabbit antisera was isolated by column chromatography on diethylaminoethyl-cellulose, whilst the anti-proMMP-3 sheep IgG was purified by affinity chromatography using proMMP-3 coupled to Affi-Gel 10 (Bio Rad, Hemel Hempstead, United Kingdom), before biotinylation with DBiotinyl-e-aminocaproic-acid-N-hydroxysuccinimide ester (Boehringer Mannheim, Lewes, United Kingdom). Before the assay, a 96 well plate was coated overnight at 4°C with 200 RI of rabbit anti-proMMP-3 IgG in phosphate buffered saline (PBS), followed by overnight blocking at 4°C with 0-5% (w/v) bovine serum albumin (BSA) in PBS-0-05% Tween 20 (BSA-PBS-Tween). After the wells were emptied and washed in PBS-Tween, either 100 RI of proMMP-3 standard (0-4-25 ng/ml) in a Wycombe, United Kingdom) in TBS was added for 30 minutes at room temperature. After three further washings in TBS and one in 0 5 mmolIl MgCl2, and 0-1 mol/l diethanolamine pH 9-6 (Mg-Di), 200 ,ul of 1 mg p-nitrophenyl phosphate (Sigma, Poole, United Kingdom) in Mg-Di was added to each well and, after colour development, absorbance was read at 405 nm. A spline curve fit was used for the almost linear plot of absorbance versus the log of doubling concentrations between 0 4 and 25 ng/ml. Two control sera, prepared by spiking normal sera with purified proMMP-3, were included in each of the 12 assays reported in this study and coefficients of variation of and 12-3% were obtained. Doubling dilutions of a number of RA sera into 1:21 horse serum in BSA-PBS-Tween gave linear values, confirming identical behaviour of standards and samples in the assay. The assay values of six RA sera were not affected by an additional four freeze-thaw cycles. Confirmation that the assay was indeed measuring proMMP-3 was obtained by adding an excess of sheep antiproMMP-3 IgG (Dr H Nagase, Kansas, USA), which competed to prevent binding of the biotinylated antibody, in contrast with the same concentration of normal sheep IgG, which was without effect on the assay value of 14 RA sera. Furthermore, incubating RA sera overnight at 37°C with an activator of proMMP-3 (2 mmol/l aminophenylmercuric acetate) caused a marked reduction in the assay value, suggesting that MMP-3 was originally present as the proenzyme, as both antibodies recognise this form in preference to active MMP-3. SF samples were initially diluted 1:21 into BSA-PBS-Tween and then further diluted in this buffer containing 1:21 horse serum to bring them on scale.
C REACTIVE PROTEIN Serum CRP was measured in the early RA and multiple organ failure patients, using radial immunodiffusion kits generously provided by The Binding Site, Birmingham, United Kingdom.
STATISTICAL ANALYSIS Significant differences between groups were determined by the Mann-Whitney U test and the Spearman rank correlation coefficient was used to examine relationships between measurements. Samples obtained before and after intra-articular injection of steroid were compared using a signed rank test for paired samples.
Results
MEASUREMENTS OF SERUM proMMP-PATIENTS WITH INFIAMMATORY AN INFLAMMATORY ARTHRITIDES
Increased concentrations of serum compared with those in a normal c were found in patients with (p < 0002), ReA (p < 0-001), est; (p < 0001) and AS (p < 0-001), patients with OA (p = 0 533) (fit established RA patients the me value of 219-7 ng/ml (range 36A4-5 was nine times greater than that ir group (24-3 ng/ml, range 3X9-68*8 three patient values were within range. By contrast, in both the e; AS patient groups, 12 had serum In the values within the control range and median values of 47-2 ng/ml (range 19-4-656-3 ng/ml) and 61-6 ng/ml (range 17-3-433-2 ng/ml), respectively. OA patients had a median value of 21 3 ng/ml (range 7 3-61 X 1 ng/ml); the ReA group had a median value of 81-9 ng/ml (range 19-5-683-0 ng/ml) and eight patient values within the control range.
-dian serum RELATIONSHIP BETWEEN SERUM AND SYNOVIAL 571 6 ng/ml) FLUID proMMP-3 CONCENTRATIONS i the control Measurement of proMMP-3 in 22 paired, ng/ml); only simultaneously obtained serum and SF the control samples collected before intra-articular inarly RA and jection of steroid in patients with RA or ReA proMMP-3 revealed several-hundredfold greater concentrations within joint fluid and a significant correlation (r= 0-8, p < 0001) with serum values (fig 2) . Western blot analysis of a 1/% (v/v) dilution of seven of these fluids revealed o only the doublet corresponding to the pro- Steroid injection into the inflamed joints of 13 o00 patients with RA caused a significant reduction°0 (p < 0 04) in serum proMMP-3 (table 2). The decrease appeared most marked for those with the greatest serum concentrations before the injection.
RELATIONSHIP OF SERUM proMMP-3 AND CRP CONCENTRATIONS
The serum concentrations of proMMP-3 and AS CRP in the early RA group showed a its with early significant correlation (r = 0-48, p < 0.04) id arthritis ( fig 3A) . However, in a group of critically ill itides and the patients with multiple organ failure, in whom the CRP concentration was greatly increased from the normal of <5 ,ug/ml to a median value of 134-5 ,ug/ml, there was no significant correlation (r = 0-29, p = 0 094) with serum proMMP-3 ( fig 3B) . Indeed, the median pr<=80o0 serum proMP-3 value of 33-8 ng/ml was not significantly different (p = 0 159) from that in the normal control group. Serum proMMP-3 (ng/ml) Figure 2 Concentrations ofproMMP-3 in synovialfluid compared with serum from inflammatory arthritides patients before intra-articular injection ofsteroid. A significant correlation was obtainedfor these paired, simultaneously collected samples. proMMP-3 in paired, simultaneously collected serum and SF samples from patients receiving intra-articular injection of steroid indicated that the inflamed joint was indeed the source of this circulatory proMMP-3: it revealed that the SF proMMP-3 concentration was severalhundredfold greater than that in the paired serum sample, and that there was a highly significant correlation between these two values. Additionally, the intra-articular injection into RA patients of a steroid with anti-monokine properties caused a significant reduction in serum concentrations of proMMP-3, emphasising the association between joint fluid and serum concentrations. however, increased plasma concentrations of HA were also obtained in OA, and there was a considerable degree of overlap with the RA group.'2 A further difference is that HA is also increased in septicaemia,'3 a condition in which we have shown proMMP-3 was not increased.
Regarding the serum concentration of proMMP-3 in other chronic inflammatory diseases, roles for IL-1 and TNFot have also been proposed in the pathology of inflammatory bowel disease, and clinical trials of an IL-1 antagonist (IL-iRa) have been initiated in patients with ulcerative colitis. '4 In keeping with this, we have detected increased proMMP-3 serum concentrations in patients with ulcerative colitis and Crohn's disease (D J Taylor, P J Whorwell, unpublished observation). TNFot and matrix metalloproteinases have also been implicated in the destruction of myelin in multiple sclerosis.'5 However, in several serum samples from three patients, serum proMMP-3 was within the normal range and showed no increase during relapse (D J Taylor, N Woodroofe, unpublished observation).
From these studies, the measurement of serum proMMP-3 appears to offer a convenient indicator of proinflammatory monokine action at sites of chronic inflammation. The availability of such a marker may prove useful in view of the current pharmacological attempts to inhibit the action or formation of these monokines in a number of chronic inflammatory diseases, including RA.
NOTE ADDED IN PROOF: While this paper was under review and after its acceptance, two other reports of increased serum proMMP-3 in RA were published. ' 
